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Background: Primary small cell carcinoma of the esophagus (SCCE) is a highly aggressive disease characterized by
early dissemination and poor prognosis. Because of the rarity of this disease, few previous studies have investigated
the biomarkers associated with its prognosis. Leucine-rich repeat-containing G-protein coupled receptor 5 (Lgr5) is
a stem cell marker and a member of the canonical Wnt-signaling cascade. However, the clinical role of Lgr5 in SCCE
remains unknown.
Methods: Tissue sections were obtained from 44 patients diagnosed with SCCE and expression of Lgr5 was
examined by immunohistochemistry. The correlations between Lgr5 expression, and clinical parameters and
prognostic significance were evaluated.
Results: Lgr5 was expressed in SCCE cancer tissues. High Lgr5 expression was significantly correlated with lymph
node metastasis (p = 0.003), late stage (p = 0.003) and unfavorable response to chemotherapy (p = 0.013) according
to RECIST 1.0 criteria. Patients with higher Lgr5 expression levels had shorter overall survival times than those with
lower expression levels.
Conclusions: These results demonstrated that overexpression of Lgr5 was significantly correlated with lymph node
metastasis, tumor stage, and response to chemotherapy. Furthermore, high levels of Lgr5 expression appeared to
be associated with poorer survival in patients with SCCE.
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Esophageal carcinoma is one of the most common ma-
lignancies in China, but primary small cell carcinoma of
the esophagus (SCCE) is a relatively rare histopatho-
logical type, accounting for only 1-2.8% of esophageal
carcinomas [1,2]. SCCE is highly aggressive, and charac-
terized by early dissemination and poor prognosis
[3-10]. A total of 5,379 cases of esophageal cancer and
2,061 cases of small cell carcinoma were recorded at Sun
Yat-sen University Cancer Center from 1994 to 2012,
including 93 cases of SCCE. Little is known about the
clinicopathological features of SCCE, and it is necessary
to identify biomarkers for predicting prognosis and for
distinguishing individuals with unfavorable prognoses.* Correspondence: xurh@sysucc.org.cn
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unless otherwise stated.The Wnt signaling pathway is important for adult tis-
sue maintenance. Perturbations in Wnt signaling cause
human cancers [11]. Leucine-rich repeat-containing G-
protein coupled receptor 5 (Lgr5) is an orphan G-protein
coupled receptor (GPCR) and a stem cell marker first
described as a Wnt target gene [12]. It is also a member of
the canonical Wnt-signaling cascade, which forms a sig-
naling gradient in the intestinal crypt, thereby regulating
cell proliferation and differentiation [13]. Lgr5 was also
identified as a marker of poor prognosis in colon, ovary
and liver cancers [14,15], and was considered to be
involved in tumorigenesis in Barrett’s esophagus and
esophageal adenocarcinoma [16].
However, the expression and potential clinical signifi-
cance of Lgr5 in SCCE has not been determined. In this
study, we analyzed the expression levels of Lgr5 and
their relationships with clinicopathological features in 44
patients with SCCE.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Clinicopathological characteristics and Lgr5
expression in tumors from 44 patients with SCCE











> = 5 cm 21 53.8
<5 cm 18 46.2
Tumor location
Upper thoracic segment 7 15.9
Middle thoracic segment 22 50.0
Lower thoracic segment 15 34.1
AJCC stage(43 available)
I/II 19 44.2
III/IV T classification(40 available) 24 55.8
T < =2 20 45.5
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Tumor tissues and patient information
A total of 44 paraffin-embedded samples were obtained
from patients diagnosed with SCCE from January 1 1994
to January 1 2012 at Sun Yat-sen University Cancer Cen-
ter. The diagnosis of SCCE had been confirmed by the
Pathology Department of Sun Yat-sen University Cancer
Center, based on the 2000 World Health Organization
histological criteria for esophageal small cell carcinoma
[17] and 2004 histological criteria for pulmonary small
cell carcinoma [18]. As described previously [10], tumor
cells were characterized by small, spindle-like, round or
ovoid shape, scarce cytoplasm, indistinct cell borders,
and an inconspicuous or absent nucleolus. Information
on the neuroendocrine markers neuron-specific enolase
(NSE), synaptophysin (Syn), chromogranin A (CgA) and
CD56 were obtained from patient pathology reports. All
patients were positive for CgA and/or Syn expression;
about 70.5% of patients were Syn-positive, 84.1% were
CgA-positive, 56.8% of cases were NSE-positive and
34.1% were CD56-positive.
Informed consent was obtained from all patients and
the study was approved by the Research Ethics Commit-
tee of Sun Yat-Sen University. No patients had received
any treatment prior to surgery or biopsy. Of the 44 sam-
ples, 29 were obtained at surgery and 15 by biopsy. The
clinicopathological records of all patients were reviewed.
The American Joint Committee on Cancer (AJCC) cli-
nical and pathologic staging system was adopted for all
patients. Overall survival (OS) was defined as the time
from the date of diagnosis to the point of death or the
last follow-up.
Immunohistochemistry (IHC)
IHC was performed to study the expression of Lgr5 in
SCCE tissues, as described previously [19]. Briefly, paraf-
fin-embedded tissue sections were baked at 60°C for 2 h,
deparaffinized, and rehydrated. After treatment with 3%
hydrogen peroxide for 30 min, the sections were put in a
high-pressure environment for antigen retrieval. Tissue
sections were incubated with rabbit anti-Lgr5 (1:400;
Abcam, United states) overnight at 4°C, then treated
with anti-rabbit secondary antibody for 40 min, followed
by treatment with diaminobenzidine tetrahydrochloride
(DAB), and counterstaining with hematoxylin. Human
colon cancer tissues with strong Lgr5 staining were used
as positive controls, based on previous reports [20]. Lgr5
immunostaining was evaluated by two independent ob-
servers who were blinded to the clinicopathological cha-
racteristics of the patients. Immunostaining scores were
awarded by two independent observers according to the
percentage and intensity of the stained cells. Positivity
values were as follows: 0 (<10%), 1 (10–25%), 2 (25–50%),
3 (50–75%), and 4 (>75%). Intensity values were asfollows: 0 (negative), 1 (weak staining), 2 (moderate stai-
ning), and 3 (strong staining). The final score was calcu-
lated by multiplying the above two values. For subsequent
Figure 1 Immunohistochemical staining of Lgr5 in cancerous tissue and adjacent normal mucosa. A: Higher levels of Lgr5 expression
were observed in tumor tissues compared with ANT (×100 magnification). Colon cancer tissue was used as a positive control (insert). B: Higher
levels of Lgr5 expression were observed in tumor tissues compared with ANT (×400 magnification). Abbreviations: T: tumor, ANT: adjacent
normal tissue.
Table 2 Correlation between clinicopathological characteristics and Lgr5 expression in patients with SCCE
Lgr5 expression







Tumor length(39 available) .256
> = 5 cm 9 12
<5 cm 11 7
Tumor location .721
Upper thoracic segment 3 4
Middle thoracic segment 11 11
Lower thoracic segment 9 6
AJCC stage(43 available) .003
I/II 15 4
III/IV 8 16
T classification(40 available) .206
T < =2 12 8
T > 2 8 12
N classification(42 available) .003
N0 13 3
N+ 9 17
M classification(43 available) .329
M0 19 14
M1 4 6
Chemotherapy response(19 available) .013
Reached CR/PR 5 1
Did not reach CR/PR 3 10
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Figure 2 Immunohistochemical staining of Lgr5 in small cell carcinoma of the esophagus (×400 magnification). A: Lgr5 expression in
stage I patients (representative slide). B: Lgr5 expression in stage IV patients (representative slide). C: Lgr5 expression in patients without lymph
node metastasis (representative slide). D: Lgr5 expression in patients with lymph node metastasis (representative slide). E: Lgr5 expression in
patients who achieved complete response during chemotherapy (representative slide). F: Lgr5 expression in patients evaluated with progressive
disease during chemotherapy (representative slide).
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and low expression was a score ≤4.
Statistical analysis
Statistical analysis was carried out using SPSS 16.0. The
significance of correlations between biomarker expres-
sion levels and clinical features were calculated using χ2
tests. Survival curves were displayed by Kaplan–Meier
analysis and differences in survival were assessed by log-
rank tests. A two-sided α-error of less than 5% (p < 0.05)
was considered as statistically significant.
Results
Expression of Lgr5 in SCCE and correlation between
expression and clinicopathologic features
Detailed information was collected for 44 patients
(Table 1). The median follow-up time for all patients
was 11.1 months (3–84.9 months). Tissue sections were
subjected to IHC to investigate Lgr5 expression levels
and to correlate these with clinicopathological features.Lgr5 was localized mainly in the cytoplasm of cancer cells
(Figure 1). Adjacent normal esophageal tissue (ANT) was
available from five patients, two of whom showed higher
Lgr5 expression levels in tumor tissues than in ANT
(representative slide shown in Figure 1). According to the
IHC scoring system, 47.7% of tumors showed high cyto-
plasmic expression of Lgr5. High Lgr5 expression levels
were significantly correlated with lymph node metastasis
(p = 0.003), late stage (p = 0.003) and unfavorable response
to chemotherapy (p = 0.013) according to RECIST 1.0 cri-
teria (Table 2, representative slides shown in Figure 2).
However, Lgr5 expression was not correlated with sex,
age, tumor type, tumor location, tumor length or distant
metastases.
Association between Lgr5 expression and patient survival
High expression of Lgr5 was associated with a shorter
overall survival time (Figure 3, p = 0.001). The overall 1-,
2-, and 5-year cumulative survival rates in patients with
high expression levels of Lgr5 were 20%, 0%, and 0%,
Figure 3 Kaplan–Meier curves for lower versus higher
expression levels of Lgr5. Nine patients were lost to follow-up.
Overall survival time was available for 35 patients.
Table 3 Univariate and multivariate analyses of
prognostic parameters in patients with SCCE
Univariate analysis Multivariate analysis
Variable No. P HR 95.0% CI p
Tumor length .045 .288 .086 .963 .043
> = 5 cm 21
<5 cm 18
Lgr5 expression .001 1.519 .346 6.659 .580
Low 23
High 21
T classification .725 .760 .276 2.090 .595
T < =2 20
T > 2 20
N classification .170 3.726 1.063 13.061 .040
N0 16
N+ 26
M classification .096 4.861 .902 26.212 .066
M0 33
M1 10
Chemotherapy .088 .229 .081 .649 .006
No 16
Yes 28
Surgery .207 1.222 .257 5.822 .801
No 11
Yes 33
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tients with low Lgr5 expression. Cox regression analysis
identified tumor length (p = 0.043), lymph node involve-
ment (p = 0.04) and chemotherapy (p = 0.006) as inde-
pendent prognostic factors (Table 3).
Discussion
SCCE is a highly metastatic disease with a median sur-
vival time of less than 1 year [21]. The recurrence rate
after surgery is very high, even in patients with early-
stage disease [22]. However, the aggressive features and
poor prognosis of SCCE found in clinical practice have
not yet been linked to any specific biomarkers. Recent
genetic discoveries based on tumor genome sequencing
suggest that the Wnt pathway plays important roles in
tumor biology [23]. Activation of the Wnt pathway re-
leases β-catenin, which interacts with T cell factor family
members to activate the transcription of downstream
target genes [24]. R-spondins potently enhance β-catenin
signaling and have been implicated in human disease
and malignancy [25,26]. Lgr5 is a receptor for R-spondin
and was shown to activate β-catenin signaling when
bound to R-spondins [25,27,28], and may be associated
with tumorigenesis via the Wnt pathway.
Iuga et al. [29] reported that Lgr5 was a novel IHC
marker for gastrointestinal neuroendocrine tumors; 88%
of primary neuroendocrine tumors and 87% of meta-
stases stained positive for cytoplasmic Lgr5. Moreover,
Lgr5 stained positive in most cases expressing CgA and
Syn (34/38). These findings were consistent with our
study, which also found high Lgr5 expression levels inSCCEs, which were rich in CgA and Syn. von Rahden
et al. [16] reported LgR5 expression in 35 of 41 (85%)
patients with esophageal adenocarcinomas with Barrett’s
esophagus, and in 16 of 19 (81%) without Barrett’s eso-
phagus. Becker et al. [30] also detected Lgr5 expression
in early esophageal squamous cells. Based on the above
findings, we examined Lgr5 expression in SCCE.
Of the 44 patients with SCCE examined by IHC, only
15.8% who presented with high levels of Lgr5 survived
for longer than 1 year after diagnosis (data not shown).
The median survival in patients with high expression
levels of Lgr5 was 7 months, which was 11 months
shorter than in patients with lower expression of Lgr5.
Less than 20% of patients (18 patients) had survived lon-
ger than 2 years at the end of follow-up, none of whom
presented with high Lgr5 expression. Our results indi-
cated that high levels of Lgr5 expression were signi-
ficantly correlated with lymph node metastasis and late
stage (stage III/IV), suggesting that high expression of
Lgr5 might predict a poor prognosis. Indeed 62% of pa-
tients with lymph node metastases failed to survive for
longer than 1 year, in accordance with a previous study
in which esophageal cancer patients with more than
four involved lymph nodes showed similar survival to
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lymph node involvement was an independent prognostic
factor, which might explain the association between high
expression of Lgr5 and poor prognosis.
SCCE is a systemic disease [21]. Chemotherapy pro-
vides the backbone of SCCE therapy [21,32], which was
in accordance with the fact that chemotherapy was
an independent prognostic factor in the present study.
Lgr5 expression may also predict response to chemo-
therapy in SCCE. High Lgr5 expression was significantly
correlated with unfavorable response in this study; only
33% of patients with high expression achieved partial/
complete responses during chemotherapy. Additionally,
Lgr5 may also predict chemotherapy response in colo-
rectal cancer [33].
A recent study suggested that GPCRs and their signal
transduction pathways may provide promising new thera-
peutic approaches [34]. They are involved in the control
of blood pressure, maintenance of kidney function, occur-
rence of neurological diseases and the progression of can-
cer [34]. Approximately 36% of currently-marketed drugs
target GPCRs [35]. Lgr5 has been suggested to be involved
in cancer progression through regulation of the Wnt
signaling pathway [25,27,28]. Lgr5 knockdown was shown
to induce cell death [36], and furthermore, a recently-
developed monoclonal antibody (KM4056) was reported
to have potent complement-dependent cytotoxicity ac-
tivity in vitro, and to show strong anti-tumor activity
in vivo [37]. Lgr5 thus remains a potential for targeted
therapy.
Overall, the results of this study suggest that Lgr5 pro-
tein expression may represent a possible prognostic
marker in SCCE patients. However, these results need to
be validated by further studies with larger sample sizes
and in randomized patient cohorts before Lgr5 IHC can
be used in clinical applications.
Conclusions
In summary, overexpression of Lgr5 was significantly
correlated with lymph node metastasis, tumor stage and
response to chemotherapy, while high levels of Lgr5
expression were also associated with poor survival in pa-
tients with SCCE.
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